Tecentriq

atezolizumab · PD-L1 Blocking Antibody

Back to Cancer Drug Encyclopedia Find Recruiting Trials with this Drug →

Indications & Uses

Locally advanced or metastatic urothelial carcinoma, non-small cell lung cancer, extensive-stage small cell lung cancer (ES-SCLC), and unresectable hepatocellular carcinoma in combination with bevacizumab.

Contraindications

None.

Side Effects & Warnings

Immune-mediated pneumonitis, hepatitis, colitis, endocrinopathies, dermatologic adverse reactions, infections, fatigue, nausea, and decreased appetite.

Drug & Dietary Interactions

Avoid systemic corticosteroids before initiating treatment unless used to manage immune-mediated adverse reactions.

Regulatory & Prescribing Information

FDA Approved Biologic (BLA 761034).

For educational and informational purposes only. Do not alter medication doses or regimens without consulting your licensed oncology physician or care team.

Patient & Caregiver Support

Ask About This Medication

Connect with an ONC-ORG counselor regarding drug access, copay relief, patient assistance programs, or related clinical trials.